Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Immunic Inc (IMUX)

Immunic Inc (IMUX)
0.9829 -0.0071 (-0.72%) 11:19 ET [NASDAQ]
0.9913 x 500 0.9962 x 500
Realtime by (Cboe BZX)
0.9913 x 500 0.9962 x 500
Realtime 1.0097 +0.0206 (-) 09:09 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9700
Day High
1.0400
Open 1.0100
Previous Close 0.9900 0.9900
Volume 498,822 498,822
Avg Vol 664,219 664,219
Stochastic %K 45.02% 45.02%
Weighted Alpha -35.38 -35.38
5-Day Change +0.0509 (+5.54%) +0.0509 (+5.54%)
52-Week Range 0.8319 - 2.1100 0.8319 - 2.1100
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,774
  • Shares Outstanding, K 95,818
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,510 K
  • EBIT $ -98 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.79

Options Overview Details

View History
  • Implied Volatility 398.95% ( -199.89%)
  • Historical Volatility 65.82%
  • IV Percentile 83%
  • IV Rank 46.95%
  • IV High 809.76% on 02/05/25
  • IV Low 35.34% on 08/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 136
  • Volume Avg (30-Day) 752
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 22,460
  • Open Int (30-Day) 21,770

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.26
  • Prior Year -0.25
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8319 +16.48%
on 04/09/25
Period Open: 1.1500
1.3500 -28.22%
on 03/25/25
-0.1810 (-15.74%)
since 03/21/25
3-Month
0.8319 +16.48%
on 04/09/25
Period Open: 0.9836
1.3900 -30.29%
on 02/21/25
-0.0146 (-1.48%)
since 01/22/25
52-Week
0.8319 +16.48%
on 04/09/25
Period Open: 1.2300
2.1100 -54.08%
on 09/19/24
-0.2610 (-21.22%)
since 04/22/24

Most Recent Stories

More News
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode

Immunic intends to use the net proceeds from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.

IMUX : 0.9829 (-0.63%)
VXF : 161.81 (+2.32%)
VTI : 258.26 (+2.24%)
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit...

IMRN : 1.7800 (+6.44%)
ULY : 4.59 (+1.10%)
IMUX : 0.9829 (-0.63%)
NMTC : 0.5471 (-3.51%)
SNGX : 2.06 (-0.72%)
TMG.VN : 0.115 (unch)
BLGO : 0.2392 (+0.25%)
FET : 14.93 (+1.56%)
ACFN : 14.5000 (+1.40%)
NRBO : 2.36 (+0.43%)
TGCB : 0.0340 (+5.26%)
SOTK : 3.75 (+1.63%)
Immunic: Q3 Earnings Snapshot

Immunic: Q3 Earnings Snapshot

IMUX : 0.9829 (-0.63%)
Immunic: Q2 Earnings Snapshot

Immunic: Q2 Earnings Snapshot

IMUX : 0.9829 (-0.63%)
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 0.9829 (-0.63%)
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 0.9829 (-0.63%)
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 0.9829 (-0.63%)
Stock Index Futures Climb on Dovish Fed Comments, PepsiCo Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.26% this morning as comments from Fed officials bolstered bets that the U.S. central bank may stand...

NOC : 468.47 (-11.83%)
JNPR : 34.49 (+1.32%)
IMUX : 0.9829 (-0.63%)
EXAS : 44.00 (+2.09%)
DDOG : 90.73 (+2.04%)
NQZ23 : 16,530.23s (-0.07%)
RIVN : 11.54 (+3.50%)
AAL : 9.13 (+0.66%)
DAL : 39.77 (+0.76%)
ELIS.FP : 21.520 (-0.37%)
LMT : 460.70 (+0.52%)
PD : 14.81 (+2.49%)
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as...

IMUX : 0.9829 (-0.63%)
Immunic to Participate in Scientific Conferences in October

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 0.9829 (-0.63%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 1.0961
2nd Resistance Point 1.0630
1st Resistance Point 1.0261
Last Price 0.9829
1st Support Level 0.9561
2nd Support Level 0.9230
3rd Support Level 0.8861

See More

52-Week High 2.1100
Fibonacci 61.8% 1.6218
Fibonacci 50% 1.4709
Fibonacci 38.2% 1.3201
Last Price 0.9829
52-Week Low 0.8319

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro